|
Re: ... did some looking back
|
3
|
Resverlogix Corp.
|
Jul 11, 2017 11:06AM
|
|
Re: ... did some looking back..no planned update..
|
1
|
Resverlogix Corp.
|
Jul 11, 2017 11:57AM
|
|
Re: Update
|
5
|
Zenith Epigenetics
|
Jul 12, 2017 01:26PM
|
|
Re: ... FYI... the BoM trial has...
|
4
|
Resverlogix Corp.
|
Jul 12, 2017 01:43PM
|
|
Re: DM
|
8
|
Resverlogix Corp.
|
Jul 13, 2017 12:06PM
|
|
ZEN-3694 Single Agent Trial Status
|
4
|
Zenith Epigenetics
|
Jul 14, 2017 01:49PM
|
|
Re: ZEN-3694 Single Agent Trial Status
|
4
|
Zenith Epigenetics
|
Jul 14, 2017 03:26PM
|
|
Re: Lobbying Firm and Resverlogix
|
3
|
Resverlogix Corp.
|
Jul 14, 2017 05:42PM
|
|
Re: ZEN-3694 Single Agent Trial Status
|
5
|
Zenith Epigenetics
|
Jul 16, 2017 11:12PM
|
|
Re: Three Months - Yeah, Right.
|
5
|
Resverlogix Corp.
|
Jul 19, 2017 10:08AM
|
|
Re: ZEN-3694 Single Agent Trial Status
|
5
|
Zenith Epigenetics
|
Jul 19, 2017 10:51AM
|
|
biOasis AGM September 6, 2017
|
|
BIOASIS TECHNOLOGIES INC
|
Jul 19, 2017 11:01AM
|
|
Gilead GS-5829 Perspective
|
4
|
Zenith Epigenetics
|
Jul 20, 2017 12:26PM
|
|
OncoFusion
|
3
|
Zenith Epigenetics
|
Jul 20, 2017 01:12PM
|
|
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
|
3
|
Resverlogix Corp.
|
Jul 25, 2017 09:48AM
|
|
Re: Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
|
5
|
Resverlogix Corp.
|
Jul 25, 2017 09:59AM
|
|
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
|
5
|
Resverlogix Corp.
|
Jul 25, 2017 10:42AM
|
|
Re: Was anyone a little nervous? Question for BDZ.....
|
4
|
Resverlogix Corp.
|
Jul 25, 2017 05:10PM
|
|
Re: Was anyone a little nervous? Question for BDZ.....
|
2
|
Resverlogix Corp.
|
Jul 25, 2017 05:29PM
|
|
Re: Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
|
4
|
Resverlogix Corp.
|
Jul 25, 2017 11:10PM
|
